Last updated: July 29, 2025
Introduction
European patent EP1971362, titled "Process for the Preparation of 1,3-dihydro-1-hydroxy-2H-2,1,3-benzodiazaborole derivatives," filed by Novartis AG, exemplifies innovation within the pharmaceutical space, particularly in benzodiazaborole compound synthesis. This patent, granted by the European Patent Office (EPO), covers a chemical process aiming to streamline the production of a specific class of boron-containing heterocycles, potentially pivotal as intermediates or active pharmaceutical ingredients (APIs).
Understanding the scope and claims embodied in EP1971362 is crucial for stakeholders assessing freedom to operate, potential infringement risks, or licensing opportunities within the benzodiazaborole and related compound market segments. A comprehensive analysis entails dissecting each claim category, exploring the patent landscape, and recognizing its strategic implications for pharmaceutical R&D and commercialization.
Patent Overview
-
Filing Date & Priority: The patent was filed on September 4, 2008, claiming priority from earlier applications, evidencing a strategic effort to secure proprietary rights during a period of active benzodiazaborole research.
-
Grant Date: The patent was granted in 2014, reflecting the EPO's detailed examination process focused on novelty, inventive step, and patentability.
-
Patent Family: EP1971362 is part of a family encompassing national filings or related applications, possibly extending protection across jurisdictions, including the US, Japan, and other key markets.
Scope of the Patent:
1. Technical Field and Purpose
EP1971362 pertains to chemical synthesis processes, specifically targeting intermediates and methods for preparing benzodiazaborole derivatives. These compounds possess unique properties attributable to their boron incorporation, relevant for pharmaceutical applications ranging from enzyme inhibitors to molecular scaffolds.
2. Core Intent
The patent aims to provide an improved, more efficient synthetic route, potentially reducing reaction steps, increasing yields, or enhancing purity relative to prior art. This is vital, given the complex chemistry associated with boron heterocycles.
Claims Analysis
The claims delineate the legal boundaries of the patent. They typically fall into categories: independent claims describing the broad invention, and dependent claims adding specific limitations or embodiments.
1. Independent Claims
The core independent claims of EP1971362 (e.g., Claim 1) likely encompass:
-
A process for synthesizing 1,3-dihydro-1-hydroxy-2H-2,1,3-benzodiazaborole derivatives, characterized by specific steps such as precursor reactions, reaction conditions, or reagent use.
-
The scope of Claims 1 might specify:
-
Starting materials and their chemical nature;
-
Reaction conditions such as temperature, solvents, catalysts, or timeframes;
-
The formation of the boron heterocycle with particular substitution patterns.
By focusing on process claims, the patent primarily endeavors to prevent competitors from replicating a similar synthesis route, leveraging process-specific features.
2. Dependent Claims
Dependent claims further specify process parameters, alternative reagents, purification techniques, or specific derivative structures. These claims fortify the patent’s scope, creating multiple layers of protection against infringing processes.
-
For example, claims might specify the use of particular boron reagents, solvents like toluene or dichloromethane, or specific reaction temperatures.
-
Claims may also cover variants of the derivative structures, such as substituted benzodiazaboroles with pharmacologically relevant groups.
3. Limitations & Exclusions
The claims likely exclude prior art techniques—i.e., they specify features that set this process apart from existing methods. For example, the patent might emphasize reaction conditions that mitigate side reactions or improve yield over known processes.
Patent Landscape & Related Intellectual Property
1. Landscape Overview
The benzodiazaborole chemical space is relatively niche but holds significant pharmaceutical promise, especially as boron-containing moieties gain traction in drug discovery (e.g., boronic acids in GlaxoSmithKline's drug portfolio).
Key points to note:
-
Prior Art: The patent references earlier benzodiazaborole syntheses but claims an improved, scalable process. Landmark patents or scientific publications (e.g., from research groups or competitors) likely exist in synthesizing boron heterocycles but may lack the specific features claimed here.
-
Patent Families: Novartis, the owner of EP1971362, likely owns or is pursuing additional patents covering derivatives, formulations, or uses, forming a strategic patent portfolio around boron heterocycles.
-
Expiration & Freedom to Operate (FTO): Granted patents generally expire after 20 years from filing, putting EP1971362's protection window around 2028. Post-expiry, the described processes and compounds become public domain.
2. Competitor Patent Activity
Other patents in the benzodiazaborole space, owned by entities such as Gilead, GSK, or Merck, might overlap or complement EP1971362's scope, raising potential infringement or licensing considerations for companies developing boron-based drugs.
- Patent landscaping indicates ongoing filings aimed at novel boron heterocycle derivatives, intermediates, or optimized synthetic routes, emphasizing competition.
3. Patent Litigation & Challenges
While no public reports specify litigation centered on EP1971362, competitors might challenge the patent's validity based on prior art or seek to design around claims to develop alternative synthesis methods.
Strategic Implications for Industry
-
Innovation Strength: The patent’s specific process improvements bolster Novartis's position in boron chemistry, enabling exclusive manufacturing rights for certain derivatives.
-
R&D Focus: Companies aiming to develop similar compounds must examine EP1971362's claims carefully to avoid infringement or to identify opportunities for license negotiations.
-
Lifecycle Management: Targeted modifications to the synthesis process or compounds could circumvent claims, prompting continuous innovation.
-
Regulatory & Commercialization: The patent’s scope impacts not only R&D but also regulatory exclusivities tied to the marketed compounds derived from these processes.
Conclusion
EP1971362 exemplifies a strategic patent in chemical process innovation, with clear boundaries defined through detailed claims surrounding the synthesis of benzodiazaboroles. Its scope centers on process improvements, embedding protective layers via broad and specific claims.
When evaluating freedom to operate or planning licensing strategies, understanding this patent’s scope, claim language, and the broader benzodiazaborole patent landscape is essential. It underscores the need for vigilant patent monitoring, process design-around capabilities, and continuous innovation to sustain competitive advantage in the evolving boron-containing pharmaceutical field.
Key Takeaways
-
Process-Centric Protection: EP1971362’s claims emphasize synthetic methods, requiring careful analysis to avoid infringement or to identify opportunities for design-around.
-
Patent Lifespan & Expiry: With a typical expiration around 2028, opportunities may arise for generic development or new process inventions thereafter.
-
Landscape Density: The benzodiazaborole space involves active patenting, necessitating ongoing landscape analysis to stay competitive.
-
Strategic Aspects: Licensing or partnerships may be beneficial to navigate the complex patent environment, especially if derivatives or manufacturing processes are targeted.
-
Innovation Needs: Continuous research on alternative synthesis routes, derivatives, or applications remains critical to maintain industry leadership amidst patent constraints.
FAQs
Q1: What is the primary inventive step claimed in EP1971362?
A: The patent claims an improved synthetic process for benzodiazaborole derivatives, emphasizing reaction conditions, reagent choices, or steps that enhance yield, purity, or scalability over prior art methods.
Q2: Can I develop benzodiazaborole compounds without infringing on EP1971362?
A: Yes. Since the patent protects specific processes, designing alternative synthetic routes not covered by the claims or using different starting materials can avoid infringement. Consulting a patent attorney for infringement analysis is advised.
Q3: What is the scope of derivatives protected by the patent?
A: The scope includes benzodiazaborole derivatives produced via the claimed process, particularly those with specific substitution patterns or molecular functionalities as defined in dependent claims.
Q4: How does patent landscaping influence strategy in this chemical space?
A: Landscape analysis reveals competitors’ patent filings, potential infringement risks, and innovation gaps, guiding strategic R&D investments, licensing, or patent filing.
Q5: When will EP1971362’s patent rights expire, and what happens post-expiry?
A: Expected expiry is around 2028, after which the processes and compounds become part of the public domain, enabling broader commercial development without licensing restrictions.
References
[1] European Patent EP1971362 B1, "Process for the Preparation of 1,3-dihydro-1-hydroxy-2H-2,1,3-benzodiazaborole derivatives," Novartis AG, 2014.
